DiaMedica Therapeutics (DMAC) Projected to Announce Quarterly Earnings on Wednesday

DiaMedica Therapeutics (NASDAQ:DMAC) will likely be announcing its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.20) per share and revenue of $13.50 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.01. On average, analysts expect DiaMedica Therapeutics to post ($0.84) EPS for the current fiscal year and ($0.81) EPS for the next fiscal year.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ DMAC opened at $10.00 on Wednesday. The business has a 50-day moving average of $7.73 and a 200-day moving average of $7.14. The stock has a market capitalization of $539.30 million, a price-to-earnings ratio of -13.89 and a beta of 0.95. DiaMedica Therapeutics has a fifty-two week low of $5.24 and a fifty-two week high of $10.42.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DMAC. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a research report on Tuesday, August 11th. Wall Street Zen upgraded DiaMedica Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Thursday, October 15th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.00.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases affecting the kidneys and nervous system. The company’s research is centered on therapies intended to address conditions with limited treatment options.

DiaMedica’s lead investigational product is DM199, a recombinant form of human tissue kallikrein-1, an enzyme involved in blood flow regulation and vascular function. The company has evaluated DM199 in clinical development programs targeting acute ischemic stroke and kidney-related diseases, including chronic kidney disease.